Table 1.
IC50 values for EGFR inhibitors (gefitinib, afatinib and AZD9291) against the proliferation of parental and resistant HCC827 cells
| Cell line | IC50 (nmol/L, mean ± SD)a | ||
|---|---|---|---|
| Gefitinib | Afatinib | AZD9291 | |
| HCC827 | 3.5 ± 0.5 | 0.7 ± 0.0 | 2.6 ± 0.3 |
| HA1 | 1372.0 ± 50.9 (292.0)b | 1677.5 ± 108.2 (2396.4)b | 5002.5 ± 509.8 (1924.0)b |
| HA2 | 3693.5 ± 470.2 (1055.3)b | 1093.5 ± 48.8 (1562.1)b | 1086.5 ± 81.3 (417.9)b |
| HG1 | 8317.5 ± 1658.2 (2376.4)b | 1595.5 ± 112.4 (2279.3)b | 119.4 ± 25.9 (45.9)b |
| HG2 | 4032.5 ± 1928.3 (1152.1)b | 392.2 ± 11.7 (560.3)b | 1111.5 ± 26.2 (427.5)b |
| HG3 | 152.7 ± 11.8 (43.6)b | 17.9 ± 5.4 (25.6)b | 124.8 ± 6.3 (48.0)b |
| HG4 | 1215.5 ± 120.9 (347.3)b | 295.1 ± 123.2 (421.6)b | 511.9 ± 2.8 (196.9)b |
Abbreviation: EGFR, epidermal growth factor receptor.
a
IC50 were determined using sulforhodamine B assays by treating cells with different concentrations of drugs for 72 h. Data are presented as means ± SD of three independent experiments.
b
Resistance ratio = IC50 (resistant cells)/IC50 (HCC827).